In Tuesday’s Wall Street session, Blueprint Medicines Corp (NASDAQ:BPMC) shares traded at $127.60, down -0.15% from the previous session.
BPMC stock price is now 36.34% away from the 50-day moving average and 36.03% away from the 200-day moving average. The market capitalization of the company currently stands at $8.24B.
With the price target maintained at $129, Wedbush recently Downgraded its rating from Outperform to Neutral for Blueprint Medicines Corp (NASDAQ: BPMC). , while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, Albers Jeffrey W., Director sold 5,000 shares of the company’s stock on May 27 ’25. The stock was sold for $505,692 at an average price of $101.14. Upon completion of the transaction, the Director now directly owns 146,630 shares in the company, valued at $18.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 27 ’25, Director Albers Jeffrey W. bought 5,000 shares of the business’s stock. A total of $505,686 was incurred on buying the stock at an average price of $101.14. A total of 3.67% of the company’s stock is owned by insiders.
During the past 12 months, Blueprint Medicines Corp has had a low of $73.04 and a high of $128.15. As of last week, the company has a debt-to-equity ratio of 2.08, a current ratio of 2.80, and a quick ratio of 2.75.
The net profit margin was -27.70% and return on equity was -47.71% for BPMC. The company reported revenue of $149.41 million for the quarter, compared to $96.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 55.45 percent.
